Michigan Senate votes to repeal drugmaker immunity shield - Bridge Michigan
Michigan Senate votes to repeal drugmaker immunity shield, potentially exposing pharmaceutical manufacturers to increased liability for drug-related harms.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers operating in or distributing to Michigan, including branded, generic, API, contract manufacturers, and 503B compounding facilities. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; bill moves to House and could become law within months.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Michigan Senate passed a bill to repeal the state's drugmaker immunity shield (likely referencing the Michigan Product Liability Act's immunity for FDA-approved drugs). If enacted, manufacturers could face product liability lawsuits for injuries caused by FDA-approved drugs.
Who it affects
All pharmaceutical manufacturers operating in or distributing to Michigan, including branded, generic, API, contract manufacturers, and 503B compounding facilities.
What you must do
Monitor legislative progress, assess potential liability exposure, and prepare legal and compliance strategies to mitigate risk.
Deadline
Immediately; bill moves to House and could become law within months.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)